Metabolism of the broad-spectrum neuropeptide growth factor antagonist: ID-Arg1, D-Phe5, D-Trp7'9, Leu1-substance P
1996

Metabolism of a Neuropeptide Growth Factor Antagonist

publication Evidence: moderate

Author Information

Author(s): DA Jones, J Cummings, SP Langdon, AJ Maclellan, T Higgins, E Rozengurt, JF Smyth

Primary Institution: Imperial Cancer Research Fund

Hypothesis

The study investigates the metabolism of antagonist D and its potential as an anti-tumor agent against neuropeptide-driven cancers.

Conclusion

Antagonist D is more stable than antagonist G and its metabolites show reduced antagonist activity.

Supporting Evidence

  • Antagonist D showed greater metabolic stability compared to antagonist G.
  • The metabolites of antagonist D lost antagonist activity against neuropeptides.
  • The study provides insights into the structure-activity relationship of neuropeptide antagonists.

Takeaway

Researchers studied how a cancer-fighting drug breaks down in the body, finding that one version of the drug works better than another.

Methodology

The study involved in vitro metabolism characterization using mouse liver homogenate and HPLC for analysis.

Limitations

The study primarily focuses on in vitro results, which may not fully represent in vivo conditions.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication